Preview
Sign-in for full Details 
Sign-in free and Explore the Exciting World of BiomedExperts:
- Over 1.500.000 Profiles
- More than 1.800 Organizations worldwide
- State of the Art Network Visualizations
- Manage your own Profile
- Locate Experts in your Country/Region
- Locate Experts in your 1. and 2. Level Network
- Connect to Experts Worldwide
NetworkView
Domenico Regoli
This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers
together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles
free of charge to researchers worldwide.
Research Profile (preview)
Chemicals & Drugs
Living Beings
Concepts & Ideas
Anatomy
Procedures
Sign-in to see full Profile
Network (preview)
66
Guerrini, Remo
63
Rizzi, Anna
61
Salvadori, Severo
31
Calo', Girolamo
24
Calò, Girolamo
23
Bigoni, Raffaella
21
Calo, Girolamo
21
Camarda, Valeria
21
Lambert, David
20
Trapella, Claudio
18
Marzola, Giuliano
16
Marzola, Erika
13
Rizzi, Daniela
11
McDonald, John
8
Caló, Girolamo
Sign-in to see all Coauthors
Publications
Sign-in to see all Publications
Sign in free and see...
Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the visualized research activity
of experts around the globe
Sign-in to see more
Geonetwork of Domenico Regoli (preview)
Cities where this author has publications
Cities where co-authors of this author have publications
Sign-in to see more
All Publications
-
2009: Trapella Claudio; Fischetti Carmela; Pela' Michela; Lazzari Ilaria; Guerrini Remo; Calo' Girolamo; Rizzi Anna; Camarda Valeria; Lambert David G; McDonald John; Regoli Domenico; Salvadori Severo
Structure-activity studies on the nociceptin/orphanin FQ receptor antagonist 1-benzyl-N-{3-[spiroisobenzofuran-1(3H),4'-piperidin-1-yl]propyl} pyrrolidine-2-carboxamide.
Bioorganic & medicinal chemistry 2009;17(14):5080-95.
-
2009: Guerrini Remo; Camarda Valeria; Trapella Claudio; Caló Girolamo; Rizzi Anna; Ruzza Chiara; Fiorini Stella; Marzola Erika; Reinscheid Rainer K; Regoli Domenico; Salvadori Severo
Further studies at neuropeptide s position 5: discovery of novel neuropeptide S receptor antagonists.
Journal of medicinal chemistry 2009;52(13):4068-71.
-
2009: Fischetti Carmela; Camarda Valeria; Rizzi Anna; Pelà Michela; Trapella Claudio; Guerrini Remo; McDonald John; Lambert David G; Salvadori Severo; Regoli Domenico; Calo' Girolamo
Pharmacological characterization of the nociceptin/orphanin FQ receptor non peptide antagonist Compound 24.
European journal of pharmacology 2009;614(1-3):50-7.
-
2009: Batuwangala Madura; Camarda Valeria; McDonald John; Marzola Erika; Lambert David G; Ng Leong L; Calo' Girolamo; Regoli Domenico; Trapella Claudio; Guerrini Remo; Salvadori Severo
Structure-activity relationship study on Tyr9 of urotensin-II(4-11): identification of a partial agonist of the UT receptor.
Peptides 2009;30(6):1130-6.
-
2009: Camarda Valeria; Fischetti Carmela; Anzellotti Nicholas; Molinari Paola; Ambrosio Caterina; Kostenis Evi; Regoli Domenico; Trapella Claudio; Guerrini Remo; Severo Salvadori; Calo Girolamo
Pharmacological profile of NOP receptors coupled with calcium signaling via the chimeric protein Galphaqi5.
Naunyn-Schmiedeberg's archives of pharmacology 2009;379(6):599-607.
-
2009: Camarda Valeria; Rizzi Anna; Ruzza Chiara; Zucchini Silvia; Marzola Giuliano; Marzola Erika; Guerrini Remo; Salvadori Severo; Reinscheid Rainer K; Regoli Domenico; Calò Girolamo
In vitro and in vivo pharmacological characterization of the neuropeptide s receptor antagonist [D-Cys(tBu)5]neuropeptide S.
The Journal of pharmacology and experimental therapeutics 2009;328(2):549-55.
-
2009: Guerrini Remo; Camarda Valeria; Trapella Claudio; Calò Girolamo; Rizzi Anna; Ruzza Chiara; Fiorini Stella; Marzola Erika; Reinscheid Rainer K; Regoli Domenico; Salvadori Severo
Synthesis and biological activity of human neuropeptide S analogues modified in position 5: identification of potent and pure neuropeptide S receptor antagonists.
Journal of medicinal chemistry 2009;52(2):524-9.
-
2008: Camarda Valeria; Trapella Claudio; Calo' Girolamo; Guerrini Remo; Rizzi Anna; Ruzza Chiara; Fiorini Stella; Marzola Erika; Reinscheid Rainer K; Regoli Domenico; Salvadori Severo
Structure-activity study at positions 3 and 4 of human neuropeptide S.
Bioorganic & medicinal chemistry 2008;16(19):8841-5.
-
2008: Rizzi A; Vergura R; Marzola G; Ruzza C; Guerrini R; Salvadori S; Regoli D; Calo G
Neuropeptide S is a stimulatory anxiolytic agent: a behavioural study in mice.
British journal of pharmacology 2008;154(2):471-9.
-
2008: Marzola Erika; Camarda Valeria; Batuwangala Madura; Lambert David G; Calo' Girolamo; Guerrini Remo; Trapella Claudio; Regoli Domenico; Tomatis Roberto; Salvadori Severo
Structure-activity relationship study of position 4 in the urotensin-II receptor ligand U-II(4-11).
Peptides 2008;29(5):674-9.
-
2008: Camarda Valeria; Trapella Claudio; Calo Girolamo; Guerrini Remo; Rizzi Anna; Ruzza Chiara; Fiorini Stella; Marzola Erika; Reinscheid Rainer K; Regoli Domenico; Salvadori Severo
Synthesis and biological activity of human neuropeptide S analogues modified in position 2.
Journal of medicinal chemistry 2008;51(3):655-8.
-
2008: Vergura Raffaella; Balboni Gianfranco; Spagnolo Barbara; Gavioli Elaine; Lambert David G; McDonald John; Trapella Claudio; Lazarus Lawrence H; Regoli Domenico; Guerrini Remo; Salvadori Severo; Caló Girolamo
Anxiolytic- and antidepressant-like activities of H-Dmt-Tic-NH-CH(CH2-COOH)-Bid (UFP-512), a novel selective delta opioid receptor agonist.
Peptides 2008;29(1):93-103.
-
2007: Lungu C; Dias J P; França C Estevão de; Ongali B; Regoli D; Moldovan F; Couture R
Involvement of kinin B1 receptor and oxidative stress in sensory abnormalities and arterial hypertension in an experimental rat model of insulin resistance.
Neuropeptides 2007;41(6):375-87.
-
2007: Tancredi Teodorico; Guerrini Remo; Marzola Erika; Trapella Claudio; Calo Girolamo; Regoli Domenico; Reinscheid Rainer K; Camarda Valeria; Salvadori Severo; Temussi Piero Andrea
Conformation-activity relationship of neuropeptide S and some structural mutants: helicity affects their interaction with the receptor.
Journal of medicinal chemistry 2007;50(18):4501-8.
-
2007: Arduin Marika; Spagnolo Barbara; Calò Girolamo; Guerrini Remo; Carrà Giacomo; Fischetti Carmela; Trapella Claudio; Marzola Erika; McDonald John; Lambert David G; Regoli Domenico; Salvadori Severo
Synthesis and biological activity of nociceptin/orphanin FQ analogues substituted in position 7 or 11 with Calpha,alpha-dialkylated amino acids.
Bioorganic & medicinal chemistry 2007;15(13):4434-43.
-
2007: Rizzi Anna; Spagnolo Barbara; Wainford Richard D; Fischetti Carmela; Guerrini Remo; Marzola Giuliano; Baldisserotto Anna; Salvadori Severo; Regoli Domenico; Kapusta Daniel R; Calo Girolamo
In vitro and in vivo studies on UFP-112, a novel potent and long lasting agonist selective for the nociceptin/orphanin FQ receptor.
Peptides 2007;28(6):1240-51.
-
2007: Gavioli Elaine C; Rizzi Anna; Marzola Giuliano; Zucchini Silvia; Regoli Domenico; Calo' Girolamo
Altered anxiety-related behavior in nociceptin/orphanin FQ receptor gene knockout mice.
Peptides 2007;28(6):1229-39.
-
2007: Spagnolo Barbara; Carrà Giacomo; Fantin Martina; Fischetti Carmela; Hebbes Chris; McDonald John; Barnes Timothy A; Rizzi Anna; Trapella Claudio; Fanton Giulia; Morari Michele; Lambert Dave G; Regoli Domenico; Calò Girolamo
Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: in vitro studies.
The Journal of pharmacology and experimental therapeutics 2007;321(3):961-7.
-
2007: Rizzi Anna; Gavioli Elaine C; Marzola Giuliano; Spagnolo Barbara; Zucchini Silvia; Ciccocioppo Roberto; Trapella Claudio; Regoli Domenico; Calò Girolamo
Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: in vivo studies.
The Journal of pharmacology and experimental therapeutics 2007;321(3):968-74.
-
2007: Nazzaro Cristiano; Rizzi Anna; Salvadori Severo; Guerrini Remo; Regoli Domenico; Zeilhofer Hanns Ulrich; Calo Girolamo
UFP-101 antagonizes the spinal antinociceptive effects of nociceptin/orphanin FQ: behavioral and electrophysiological studies in mice.
Peptides 2007;28(3):663-9.
-
2006: Vergura Raffaella; Valenti Elena; Hebbes Christopher P; Gavioli Elaine C; Spagnolo Barbara; McDonald John; Lambert David G; Balboni Gianfranco; Salvadori Severo; Regoli Domenico; Calo' Girolamo
Dmt-Tic-NH-CH2-Bid (UFP-502), a potent DOP receptor agonist: in vitro and in vivo studies.
Peptides 2006;27(12):3322-30.
-
2006: Lazzeri Massimo; Calò Girolamo; Spinelli Michele; Malaguti Silvia; Guerrini Remo; Salvadori Severo; Beneforti Patrizia; Regoli Domenico; Turini Damiano
Daily intravesical instillation of 1 mg nociceptin/orphanin FQ for the control of neurogenic detrusor overactivity: a multicenter, placebo controlled, randomized exploratory study.
The Journal of urology 2006;176(5):2098-102.
-
2006: Rizzi Anna; Nazzaro Cristiano; Marzola G Giuliano; Zucchini Silvia; Trapella Claudio; Guerrini Remo; Zeilhofer Hanns Ulrich; Regoli Domenico; Calo' Girolamo
Endogenous nociceptin/orphanin FQ signalling produces opposite spinal antinociceptive and supraspinal pronociceptive effects in the mouse formalin test: pharmacological and genetic evidences.
Pain 2006;124(1-2):100-8.
-
2006: Roth Adelheid L; Marzola Erika; Rizzi Anna; Arduin Marika; Trapella Claudio; Corti Corrado; Vergura Raffaella; Martinelli Prisca; Salvadori Severo; Regoli Domenico; Corsi Mauro; Cavanni Paolo; Caló Girolamo; Guerrini Remo
Structure-activity studies on neuropeptide S: identification of the amino acid residues crucial for receptor activation.
The Journal of biological chemistry 2006;281(30):20809-16.
-
2006: Trapella Claudio; Guerrini Remo; Piccagli Laura; Calo' Girolamo; Carra' Giacomo; Spagnolo Barbara; Rubini Samantha; Fanton Giulia; Hebbes Christopher; McDonald John; Lambert David G; Regoli Domenico; Salvadori Severo
Identification of an achiral analogue of J-113397 as potent nociceptin/orphanin FQ receptor antagonist.
Bioorganic & medicinal chemistry 2006;14(3):692-704.
-
2006: Camarda Valeria; Spagnol Martina; Song Wei; Vergura Raffaella; Roth Adelheid L; Thompson Jonathan P; Rowbotham David J; Guerrini Remo; Marzola Erika; Salvadori Severo; Cavanni Paolo; Regoli Domenico; Douglas Stephen A; Lambert David G; Calò Girolamo
In vitro and in vivo pharmacological characterization of the novel UT receptor ligand [Pen5,DTrp7,Dab8]urotensin II(4-11) (UFP-803).
British journal of pharmacology 2006;147(1):92-100.
-
2005: Carra' G; Calo' G; Spagnolo B; Guerrini R; Arduin M; Marzola E; Trapella C; Regoli D; Salvadori S
Tryptophan replacement in the nociceptin/orphanin FQ receptor ligand Ac-RYYRWK-NH2.
The journal of peptide research : official journal of the American Peptide Society 2005;66(1):39-47.
-
2005: Guerrini Remo; Caló Girolamo; Lambert David G; Carrá Giacomo; Arduin Marika; Barnes Tim A; McDonald John; Rizzi Daniela; Trapella Claudio; Marzola Erika; Rowbotham David J; Regoli Domenico; Salvadori Severo
N- and C-terminal modifications of nociceptin/orphanin FQ generate highly potent NOP receptor ligands.
Journal of medicinal chemistry 2005;48(5):1421-7.
-
2005: Tancredi Teodorico; Carrà Giacomo; Guerrini Remo; Arduin Marika; Calò Girolamo; Regoli Domenico; Salvadori Severo; Temussi Piero Andrea
The interaction of highly helical structural mutants with the NOP receptor discloses the role of the address domain of nociceptin/orphanin FQ.
Chemistry (Weinheim an der Bergstrasse, Germany) 2005;11(7):2061-70.
-
2005: Carrà Giacomo; Rizzi Anna; Guerrini Remo; Barnes Timothy A; McDonald John; Hebbes Christopher P; Mela Flora; Kenigs Velga A; Marzola Giuliano; Rizzi Daniela; Gavioli Elaine; Zucchini Silvia; Regoli Domenico; Morari Michele; Salvadori Severo; Rowbotham David J; Lambert David G; Kapusta Daniel R; Calo' Girolamo
[(pF)Phe4,Arg14,Lys15]N/OFQ-NH2 (UFP-102), a highly potent and selective agonist of the nociceptin/orphanin FQ receptor.
The Journal of pharmacology and experimental therapeutics 2005;312(3):1114-23.
-
2005: Guerrini Remo; Camarda Valeria; Marzola Erika; Arduin Marika; Calo Girolamo; Spagnol Martina; Rizzi Anna; Salvadori Severo; Regoli Domenico
Structure-activity relationship study on human urotensin II.
Journal of peptide science : an official publication of the European Peptide Society 2005;11(2):85-90.
-
2005: Calo Girolamo; Guerrini Remo; Rizzi Anna; Salvadori Severo; Burmeister Melissa; Kapusta Daniel R; Lambert David G; Regoli Domenico
UFP-101, a peptide antagonist selective for the nociceptin/orphanin FQ receptor.
CNS drug reviews 2005;11(2):97-112.
-
2004: Vergura Raffaella; Camarda Valeria; Rizzi Anna; Spagnol Martina; Guerrini Remo; Calo' Girolamo; Salvadori Severo; Regoli Domenico
Urotensin II stimulates plasma extravasation in mice via UT receptor activation.
Naunyn-Schmiedeberg's archives of pharmacology 2004;370(5):347-52.
-
2004: Camarda Valeria; Song Wei; Marzola Erika; Spagnol Martina; Guerrini Remo; Salvadori Severo; Regoli Domenico; Thompson Jonathan P; Rowbotham David J; Behm David J; Douglas Stephen A; Calo' Girolamo; Lambert David G
Urantide mimics urotensin-II induced calcium release in cells expressing recombinant UT receptors.
European journal of pharmacology 2004;498(1-3):83-6.
-
2004: Gavioli E C; Vaughan C W; Marzola G; Guerrini R; Mitchell V A; Zucchini S; De Lima T C M; Rae G A; Salvadori S; Regoli D; Calo' G
Antidepressant-like effects of the nociceptin/orphanin FQ receptor antagonist UFP-101: new evidence from rats and mice.
Naunyn-Schmiedeberg's archives of pharmacology 2004;369(6):547-53.
-
2004: Guerrini R; Carra' G; Calo' G; Trapella C; Marzola E; Rizzi D; Regoli D; Salvadori S
Nonpeptide/peptide chimeric ligands for the nociceptin/orphanin FQ receptor: design, synthesis and in vitro pharmacological activity.
The journal of peptide research : official journal of the American Peptide Society 2004;63(6):477-84.
-
2003: Ongali Brice; Campos Maria Martha; Bregola Gianni; Rodi Donata; Regoli Domenico; Thibault Gaétan; Simonato Michele; Couture Réjean
Autoradiographic analysis of rat brain kinin B1 and B2 receptors: normal distribution and alterations induced by epilepsy.
The Journal of comparative neurology 2003;461(4):506-19.
-
2003: Ongali Brice; Buck Hudson de Sousa; Cloutier Frank; Legault Francine; Regoli Domenico; Lambert Chantal; Thibault Gaétan; Couture Réjean
Chronic effects of angiotensin-converting enzyme inhibition on kinin receptor binding sites in the rat spinal cord.
American journal of physiology. Heart and circulatory physiology 2003;284(6):H1949-58.
-
2003: Gavioli E C; Marzola G; Guerrini R; Bertorelli R; Zucchini S; De Lima T C M; Rae G A; Salvadori S; Regoli D; Calo G
Blockade of nociceptin/orphanin FQ-NOP receptor signalling produces antidepressant-like effects: pharmacological and genetic evidences from the mouse forced swimming test.
The European journal of neuroscience 2003;17(9):1987-90.
-
2003: Lazzeri Massimo; Calò Girolamo; Spinelli Michele; Guerrini Remo; Salvadori Severo; Beneforti Patrizia; Sandri Sandro; Regoli Domenico; Turini Damiano
Urodynamic effects of intravesical nociceptin/orphanin FQ in neurogenic detrusor overactivity: a randomized, placebo-controlled, double-blind study.
Urology 2003;61(5):946-50.
-
2003: Guerrini Remo; Rizzi Daniela; Zucchini Marina; Tomatis Roberto; Regoli Domenico; Calo' Girolamo; Salvadori Severo
Nociceptin/Orphanin FQ(1-13)NH2 analogues modified in the Phe1-Gly2 peptide bond.
Bioorganic & medicinal chemistry letters 2003;13(3):365-8.
-
2003: Vianna Rose Mari J; Ongali Brice; Regoli Domenico; Calixto João Batista; Couture Réjean
Up-regulation of kinin B1 receptor in the lung of streptozotocin-diabetic rat: autoradiographic and functional evidence.
British journal of pharmacology 2003;138(1):13-22.
-
2002: Rizzi Anna; Rizzi Daniela; Marzola Giuliano; Regoli Domenico; Larsen Bjarne Due; Petersen Jorgen Soberg; Calo' Girolamo
Pharmacological characterization of the novel nociceptin/orphanin FQ receptor ligand, ZP120: in vitro and in vivo studies in mice.
British journal of pharmacology 2002;137(3):369-74.
-
2002: Camarda Valeria; Guerrini Remo; Kostenis Evi; Rizzi Anna; Calò Girolamo; Hattenberger Almut; Zucchini Marina; Salvadori Severo; Regoli Domenico
A new ligand for the urotensin II receptor.
British journal of pharmacology 2002;137(3):311-4.
-
2002: Rizzi Anna; Salis Maria Bonaria; Ciccocioppo Roberto; Marzola Giuliano; Bigoni Raffaella; Guerrini Remo; Massi Maurizio; Madeddu Paolo; Salvadori Severo; Regoli Domenico; Calo' Girolamo
Pharmacological characterisation of [(pX)Phe4]nociceptin(1-13)NH2 analogues. 2. In vivo studies.
Naunyn-Schmiedeberg's archives of pharmacology 2002;365(6):450-6.
-
2002: Bigoni Raffaella; Rizzi Daniela; Rizzi Anna; Camarda Valeria; Guerrini Remo; Lambert David G; Hashiba Eiji; Berger Hartmut; Salvadori Severo; Regoli Domenico; Calo' Girolamo
Pharmacological characterisation of [(pX)Phe4]nociceptin(1-13)amide analogues. 1. In vitro studies.
Naunyn-Schmiedeberg's archives of pharmacology 2002;365(6):442-9.
-
2002: Camarda V; Rizzi A; Calo G; Guerrini R; Salvadori S; Regoli D
Pharmacological profile of hemokinin 1: a novel member of the tachykinin family.
Life sciences 2002;71(4):363-70.
-
2002: Bigoni R; Caò G; Rizzi A; Okawa H; Regoli D; Smart D; Lambert D G
Effects of naloxone benzoylhydrazone on native and recombinant nociceptin/orphanin FQ receptors.
Canadian journal of physiology and pharmacology 2002;80(5):407-12.
-
2002: Calo Girolamo; Rizzi Anna; Rizzi Daniela; Bigoni Raffaella; Guerrini Remo; Marzola Giuliano; Marti Matteo; McDonald John; Morari Michele; Lambert David G; Salvadori Severo; Regoli Domenico
[Nphe1,Arg14,Lys15]nociceptin-NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor.
British journal of pharmacology 2002;136(2):303-11.
-
2002: Camarda V; Rizzi A; Calo G; Wirth K; Regoli D
Pharmacological characterisation of novel kinin B2 receptor ligands.
Canadian journal of physiology and pharmacology 2002;80(4):281-6.
-
2002: Calo' Girolamo; Rizzi Anna; Bigoni Raffaella; Guerrini Remo; Salvadori Severo; Regoli Domenico
Pharmacological profile of nociceptin/orphanin FQ receptors.
Clinical and experimental pharmacology & physiology 2002;29(3):223-8.
-
2002: Camarda Valeria; Rizzi Anna; Calò Girolamo; Gendron Gabrielle; Perron Stephan I; Kostenis Evi; Zamboni Paolo; Mascoli Francesco; Regoli Domenico
Effects of human urotensin II in isolated vessels of various species; comparison with other vasoactive agents.
Naunyn-Schmiedeberg's archives of pharmacology 2002;365(2):141-9.
-
2002: Rizzi Daniela; Rizzi Anna; Bigoni Raffaella; Camarda Valeria; Marzola Giuliano; Guerrini Remo; De Risi Carmela; Regoli Domenico; Calo' Girolamo
[Arg(14),Lys(15)]nociceptin, a highly potent agonist of the nociceptin/orphanin FQ receptor: in vitro and in vivo studies.
The Journal of pharmacology and experimental therapeutics 2002;300(1):57-63.
-
2001: Di Giannuario A; Rizzi A; Pieretti S; Guerrini R; Bertorelli R; Salvadori S; Regoli D; Calo G
Studies on the antinociceptive effect of [Nphe1]nociceptin(1-13)NH2 in mice.
Neuroscience letters 2001;316(1):25-8.
-
2001: Lazzeri M; Calò G; Spinelli M; Guerrini R; Beneforti P; Sandri S; Zanollo A; Regoli D; Turini D
Urodynamic and clinical evidence of acute inhibitory effects of intravesical nociceptin/orphanin FQ on detrusor overactivity in humans: a pilot study.
The Journal of urology 2001;166(6):2237-40.
-
2001: Guerrini R; Caló G; Bigoni R; Rizzi D; Rizzi A; Zucchini M; Varani K; Hashiba E; Lambert D G; Toth G; Borea P A; Salvadori S; Regoli D
Structure-activity studies of the Phe(4) residue of nociceptin(1-13)-NH(2): identification of highly potent agonists of the nociceptin/orphanin FQ receptor.
Journal of medicinal chemistry 2001;44(23):3956-64.
-
2001: Rizzi A; Marzola G; Bigoni R; Guerrini R; Salvadori S; Mogil J S; Regoli D; Calò G
Endogenous nociceptin signaling and stress-induced analgesia.
Neuroreport 2001;12(14):3009-13.
-
2001: Rizzi D; Bigoni R; Rizzi A; Jenck F; Wichmann J; Guerrini R; Regoli D; Calo G
Effects of Ro 64-6198 in nociceptin/orphanin FQ-sensitive isolated tissues.
Naunyn-Schmiedeberg's archives of pharmacology 2001;363(5):551-5.
-
2001: Guerrini R; Calo' G; Bigoni R; Rizzi D; Regoli D; Salvadori S
Structure-activity relationship of [Nphe1]-NC-(1-13)-NH2, a pure and selective nociceptin/orphanin FQ receptor antagonist.
The journal of peptide research : official journal of the American Peptide Society 2001;57(3):215-22.
-
2001: Rizzi A; Bigoni R; Marzola G; Guerrini R; Salvadori S; Regoli D; Calo' G
Characterization of the locomotor activity-inhibiting effect of nociceptin/orphanin FQ in mice.
Naunyn-Schmiedeberg's archives of pharmacology 2001;363(2):161-5.
-
2000: Bigoni R; Rizzi A; Rizzi D; Becker J A; Kieffer B L; Simonin F; Regoli D; Calo G
In vitro pharmacological profile of peptide III-BTD: a novel ligand for nociceptin/orphanin FQ and opioid receptors.
Life sciences 2000;68(2):233-9.
-
2000: Quartara L; Ricci R; Meini S; Patacchini R; Giolitti A; Amadesi S; Rizzi C; Rizzi A; Varani K; Borea P A; Maggi C A; Regoli D
Ala scan analogues of HOE 140. Synthesis and biological activities.
European journal of medicinal chemistry 2000;35(11):1001-10.
-
2000: Rizzi A; Bigoni R; Marzola G; Guerrini R; Salvadori S; Regoli D; Calo G
The nociceptin/orphanin FQ receptor antagonist, [Nphe1]NC(1-13)NH2, potentiates morphine analgesia.
Neuroreport 2000;11(11):2369-72.
-
2000: Calo' G; Bigoni R; Rizzi A; Guerrini R; Salvadori S; Regoli D
Nociceptin/orphanin FQ receptor ligands.
Peptides 2000;21(7):935-47.
-
2000: Guerrini R; Calo' G; Rizzi A; Bigoni R; Rizzi D; Regoli D; Salvadori S
Structure-activity relationships of nociceptin and related peptides: comparison with dynorphin A.
Peptides 2000;21(7):923-33.
-
2000: Guerrini R; Caló G; Bigoni R; Rizzi A; Varani K; Toth G; Gessi S; Hashiba E; Hashimoto Y; Lambert D G; Borea P A; Tomatis R; Salvadori S; Regoli D
Further studies on nociceptin-related peptides: discovery of a new chemical template with antagonist activity on the nociceptin receptor.
Journal of medicinal chemistry 2000;43(15):2805-13.
-
2000: Regoli D
Toward a new anti-inflammatory and analgesic agent.
Proceedings of the National Academy of Sciences of the United States of America 2000;97(14):7676-7.
-
2000: Bigoni R; Calo' G; Rizzi A; Guerrini R; De Risi C; Hashimoto Y; Hashiba E; Lambert D G; Regoli D
In vitro characterization of J-113397, a non-peptide nociceptin/orphanin FQ receptor antagonist.
Naunyn-Schmiedeberg's archives of pharmacology 2000;361(5):565-8.
-
2000: Calo' G; Guerrini R; Rizzi A; Salvadori S; Regoli D
Pharmacology of nociceptin and its receptor: a novel therapeutic target.
British journal of pharmacology 2000;129(7):1261-83.
-
2000: Calo' G; Guerrini R; Bigoni R; Rizzi A; Marzola G; Okawa H; Bianchi C; Lambert D G; Salvadori S; Regoli D
Characterization of [Nphe(1)]nociceptin(1-13)NH(2), a new selective nociceptin receptor antagonist.
British journal of pharmacology 2000;129(6):1183-93.
-
1999: Rizzi C; Rizzi A; Calò G; Jorizzo G; Agnello G; Mollica G; Inamura N; Regoli D
Characterization of FR 172357, a new non-peptide bradykinin B(2) receptor antagonist, in human, pig and rabbit preparations.
European journal of pharmacology 1999;386(1):25-31.
-
1999: Rizzi A; Bigoni R; Caló G; Guerrini R; Salvadori S; Regoli D
[Nphe(1)]nociceptin-(1-13)-NH(2) antagonizes nociceptin effects in the mouse colon.
European journal of pharmacology 1999;385(2-3):R3-5.
-
1999: Salvadori S; Guerrini R; Calo G; Regoli D
Structure-activity studies on nociceptin/orphanin FQ: from full agonist, to partial agonist, to pure antagonist.
Farmaco (Società chimica italiana : 1989) 1999;54(11-12):810-25.
-
1999: Rizzi A; Rizzi C; Amadesi S; Calo' G; Varani K; Inamura N; Regoli D
Pharmacological characterisation of the first non-peptide bradykinin B2 receptor agonist FR 190997: an in vitro study on human, rabbit and pig vascular B2 receptors.
Naunyn-Schmiedeberg's archives of pharmacology 1999;360(4):361-7.
-
1999: Varani K; Rizzi A; Calo G; Bigoni R; Toth G; Guerrini R; Gessi S; Salvadori S; Borea P A; Regoli D
Pharmacology of [Tyr1]nociceptin analogs: receptor binding and bioassay studies.
Naunyn-Schmiedeberg's archives of pharmacology 1999;360(3):270-7.
-
1999: Meini S; Quartara L; Rizzi A; Patacchini R; Cucchi P; Giolitti A; Calò G; Regoli D; Criscuoli M; Maggi C A
MEN 11270, A novel selective constrained peptide antagonist with high affinity at the human B2 kinin receptor.
The Journal of pharmacology and experimental therapeutics 1999;289(3):1250-6.
-
1999: Bigoni R; Giuliani S; Calo' G; Rizzi A; Guerrini R; Salvadori S; Regoli D; Maggi C A
Characterization of nociceptin receptors in the periphery: in vitro and in vivo studies.
Naunyn-Schmiedeberg's archives of pharmacology 1999;359(3):160-7.
-
1999: Madeddu P; Salis M B; Milia A F; Emanueli C; Guerrini R; Regoli D; Calò G
Cardiovascular effects of nociceptin in unanesthetized mice.
Hypertension 1999;33(3):914-9.
-
1999: Bregola G; Varani K; Gessi S; Beani L; Bianchi C; Borea P A; Regoli D; Simonato M
Changes in hippocampal and cortical B1 bradykinin receptor biological activity in two experimental models of epilepsy.
Neuroscience 1999;92(3):1043-9.
-
1999: Rizzi A; Calò G; Trevisani M; Tognetto M; Fabbri L; Mapp C; Guerrini R; Salvadori S; Regoli D; Geppetti P
Nociceptin receptor activation inhibits tachykinergic non adrenergic non cholinergic contraction of guinea pig isolated bronchus.
Life sciences 1999;64(13):PL157-63.
-
1998: Varani K; Calo G; Rizzi A; Merighi S; Toth G; Guerrini R; Salvadori S; Borea P A; Regoli D
Nociceptin receptor binding in mouse forebrain membranes: thermodynamic characteristics and structure activity relationships.
British journal of pharmacology 1998;125(7):1485-90.
-
1998: Rizzi A; Quaglio D; Vasquez G; Mascoli F; Amadesi S; Calò G; Regoli D; Zamboni P
Effects of vasoactive agents in healthy and diseased human saphenous veins.
Journal of vascular surgery : official publication, the Society for Vascular Surgery [and] International Society for Cardiovascular Surgery, North American Chapter 1998;28(5):855-61.
-
1998: Calò G; Rizzi A; Marzola G; Guerrini R; Salvadori S; Beani L; Regoli D; Bianchi C
Pharmacological characterization of the nociceptin receptor mediating hyperalgesia in the mouse tail withdrawal assay.
British journal of pharmacology 1998;125(2):373-8.
-
1998: Calo' G; Guerrini R; Bigoni R; Rizzi A; Bianchi C; Regoli D; Salvadori S
Structure-activity study of the nociceptin(1-13)-NH2 N-terminal tetrapeptide and discovery of a nociceptin receptor antagonist.
Journal of medicinal chemistry 1998;41(18):3360-6.
-
1998: Emanueli C; Grady E F; Madeddu P; Figini M; Bunnett N W; Parisi D; Regoli D; Geppetti P
Acute ACE inhibition causes plasma extravasation in mice that is mediated by bradykinin and substance P.
Hypertension 1998;31(6):1299-304.
-
1998: Guerrini R; Calo G; Rizzi A; Bigoni R; Bianchi C; Salvadori S; Regoli D
A new selective antagonist of the nociceptin receptor.
British journal of pharmacology 1998;123(2):163-5.
-
1997: Gessi S; Rizzi A; Calò G; Agnello G; Jorizzo G; Mollica G; Borea P A; Regoli D
Human vascular kinin receptors of the B2 type characterized by radioligand binding.
British journal of pharmacology 1997;122(7):1450-4.
-
1997: Rizzi A; Calò G; Amadesi S; Regoli D
Kinin B1 and B2 receptors in pig vessels: characterization of two monoreceptor systems.
Naunyn-Schmiedeberg's archives of pharmacology 1997;356(5):662-70.
-
1997: Cellier E; Barbot L; Regoli D; Couture R
Cardiovascular and behavioural effects of intracerebroventricularly administered tachykinin NK3 receptor antagonists in the conscious rat.
British journal of pharmacology 1997;122(4):643-54.
-
1997: Regoli D; Rizzi A; Calò G
Pharmacology of the kallikrein-kinin system.
Pharmacological research : the official journal of the Italian Pharmacological Society 1997;35(6):513-5.
-
1997: Calò G; Rizzi A; Bodin M; Neugebauer W; Salvadori S; Guerrini R; Bianchi C; Regoli D
Pharmacological characterization of nociceptin receptor: an in vitro study.
Canadian journal of physiology and pharmacology 1997;75(6):713-8.
-
1997: Rizzi A; Gobeil F; Bogoni G; Calò G; Campobasso C; Inamura N; Regoli D
Antagonistic effects of FR 173657 on human, pig, rabbit, and guinea pig kinin receptors: an in vitro study.
Canadian journal of physiology and pharmacology 1997;75(6):601-8.
-
1997: Figini M; Emanueli C; Bertrand C; Sicuteri R; Regoli D; Geppetti P
Differential activation of the epithelial and smooth muscle NK1 receptors by synthetic tachykinin agonists in guinea-pig trachea.
British journal of pharmacology 1997;121(4):773-81.
-
1997: Guerrini R; Calo G; Rizzi A; Bianchi C; Lazarus L H; Salvadori S; Temussi P A; Regoli D
Address and message sequences for the nociceptin receptor: a structure-activity study of nociceptin-(1-13)-peptide amide.
Journal of medicinal chemistry 1997;40(12):1789-93.
-
1997: Regoli D; Nguyen K; Caló G
Neurokinin receptors. Comparison of data from classical pharmacology, binding, and molecular biology.
Annals of the New York Academy of Sciences 1997;812():144-6.
-
1997: Rizzi A; Gobeil F; Calò G; Inamura N; Regoli D
FR 173657: a new, potent, nonpeptide kinin B2 receptor antagonist. An in vitro study.
Hypertension 1997;29(4):951-6.
-
1997: Calò G; Rizzi A; Traina L; Regoli D
Pharmacological characterization of a vasopressin V1 receptor in the isolated human gastric artery.
Life sciences 1997;60(4-5):PL63-8.
Sign-in to see more